Christian Frerker
A5024507851- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Aortic Disease and Treatment Approaches
- Cardiac Structural Anomalies and Repair
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac Imaging and Diagnostics
- Cardiac, Anesthesia and Surgical Outcomes
- Mechanical Circulatory Support Devices
- Pulmonary Hypertension Research and Treatments
- Cardiac and Coronary Surgery Techniques
- Coronary Interventions and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Venous Thromboembolism Diagnosis and Management
- Congenital Heart Disease Studies
- Vascular Procedures and Complications
- Cardiomyopathy and Myosin Studies
- Cardiovascular Syncope and Autonomic Disorders
- Acute Ischemic Stroke Management
- Heart Failure Treatment and Management
- Cardiac Arrest and Resuscitation
- Cardiovascular Issues in Pregnancy
German Centre for Cardiovascular Research
2021-2025
University Hospital Schleswig-Holstein
2021-2025
University of Lübeck
2021-2025
Universitäres Kinderwunschzentrum Lübeck
2021-2025
University Hospital Cologne
2019-2023
University of Cologne
2019-2023
Asklepios Klinik St. Georg
2012-2021
Centrum für Integrierte Onkologie
2019-2020
Leipzig Heart Institute
2019-2020
Asklepios
2019
Transcatheter aortic valve replacement (TAVR) is an effective treatment option for high-risk patients with severe stenosis. Different from surgery, transcatheter deployment of valves requires either a balloon-expandable or self-expandable system. A randomized comparison these 2 systems has not been performed.To determine whether the device associated better success rate than device.The CHOICE study was investigator-initiated trial in stenosis and anatomy suitable transfemoral TAVR procedure....
We sought to evaluate the outcomes of transcatheter mitral valve replacement (TMVR) for patients with degenerated bioprostheses [valve-in-valve (ViV)], failed annuloplasty rings [valve-in-ring (ViR)], and severe annular calcification [valve-in-mitral (ViMAC)].From TMVR multicentre registry, procedural clinical ViV, ViR, ViMAC were compared according Mitral Valve Academic Research Consortium (MVARC) criteria. A total 521 mean Society Thoracic Surgeons score 9.0 ± 7.0% underwent (322 141 58...
Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic stenosis. The aim of the ADVANCE study was evaluate outcomes following a self-expanding transcatheter system fully monitored, multi-centre 'real-world' patient population highly experienced centres.Patients severe stenosis at surgical whom CoreValve System decided by Heart Team were included. Endpoints composite major adverse cardiovascular and cerebrovascular events (MACCE;...
Abstract Background and Aims Risk stratification for mitral valve transcatheter edge-to-edge repair (M-TEER) is paramount in the decision-making process to appropriately select patients with severe secondary regurgitation (SMR). This study sought develop validate an artificial intelligence-derived risk score (EuroSMR score) predict 1-year outcomes (survival or survival + clinical improvement) SMR undergoing M-TEER. Methods An was developed from EuroSMR cohort (4172 428 treated M-TEER...
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There no data on long-term outcomes after ViV. Our aim was perform a large-scale assessment of survival and reintervention ViV.A total 1006 ViV performed more than 5 years ago [mean age 77.7 ± 9.7 years; 58.8% male; median STS-PROM score 7.3% (4.2-12.0)] were included in the analysis. Patients treated with Medtronic self-expandable valves (CoreValve/Evolut, Inc., Minneapolis, MN, USA)...
Background— Transcatheter valve implantation inside failed bioprosthetic surgical valves (valve-in-valve [ViV]) may offer an advantage over reoperation. Supra-annular transcatheter position be advantageous in achieving better hemodynamics after ViV. Our objective was to define targets for that would improve Methods and Results— Cases from the Valve-in-Valve International Data (VIVID) registry were analyzed using centralized core laboratory assessment blinded clinical events. Multivariate...
Peri-procedural transcatheter valve embolization and migration (TVEM) is a rare but potentially devastating complication of aortic implantation (TAVI). We sought to assess the incidence, causes, outcome TVEM in large multicentre cohort.We recorded cases peri-procedural patients undergoing TAVI between January 2010 December 2017 from 26 international sites. occurred 273/29 636 (0.92%) (age 80.8 ± 7.3 years; 53.8% female), which 217 were ascending aorta 56 left ventricle. The use...
Transcatheter aortic valve implantation (TAVI) has become the standard treatment for patients with severe stenosis at high surgical risk and may be considered intermediate risk. During last few years, an increasing number of low have been treated TAVI. In this study, low-risk undergoing isolated TAVI or replacement (SAVR) were analysed using data from German Aortic Valve Registry (GARY).All a Society Thoracic Surgeons Score <4% SAVR in 2014 2015 evaluated. A total 20 549 remained further...